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DOI 10.1016/j.ccr.2010.06.013SUMMARYColonic cancers with a serrated morphology have been proposed to comprise a molecularly distinct tumor
entity following an alternative pathway of genetic alterations independently of APC mutations. We demon-
strate that intestinal epithelial cell specific expression of oncogenic K-rasG12D in mice induces serrated
hyperplasia, which is characterized by p16ink4a overexpression and induction of senescence. Deletion of
Ink4a/Arf in K-rasG12D expressing mice prevents senescence and leads to invasive, metastasizing carci-
nomas with morphological and molecular alterations comparable to human KRASmutated serrated tumors.
Thus, we suggest that oncogenic K-ras represents a key player during an alternative, serrated pathway to
colorectal cancer and hence propose RAS-RAF-MEK signaling apart from APC as an additional gatekeeper
in colorectal tumor development.INTRODUCTION
Despite significant improvements in prevention, colorectal
cancer remains the thirdmost commoncancer aswell as the third
leading cause of cancer-associated death worldwide (Jemal
et al., 2009; Kamangar et al., 2006). An exact understanding
of the molecular events during carcinogenesis is crucial to
develop efficient preventive and therapeutic strategies. The
discovery of the genetic basis for familial adenomatous polyposis
(FAP), thedemonstration that genetic alterationsof adenomatous
polyposis coli (APC) are found in the majority of sporadic colo-
rectal neoplasms (Vogelstein et al., 1988), and the fact that loss
of APC is sufficient to induce tumorigenesis led to the definition
of APC as the ‘‘gatekeeper’’ of colonic carcinogenesis (Kinzler
and Vogelstein, 1996). APC mutations lead to chromosomal
instability (CIN) and followed by additional mutations in tumor
suppressors and oncogenes along the adenoma-carcinoma
sequence ultimately to invasive cancer (Lengauer et al., 1998).
However, accumulating evidence suggests that certain colo-
rectal tumors do not follow this classical pathway and may ariseSignificance
Initiation of serrated tumors that follow the so-called alternative
BRAF mutations. We present a mouse model that develops c
human serrated tumors harboring KRASmutations. Thus, we p
and therapeutic studies of serrated cancers and highlight a s
cence and Ink4a/Arf in colon cancer progression.independently of APC mutations. Because of their distinct
histological and molecular features this group of tumors, which
may explain 7.5% of all and 17.5% of proximal colorectal
cancers, has been proposed to follow an alternative pathway,
the so-called serrated route to cancer (Jass, 2007; Makinen,
2007; Noffsinger, 2009). This class of tumors comprises
a morphologically and presumably molecularly heterogenous
group ranging from hyperplastic polyps (HP), sessile serrated
polyps (SSA), traditional serrated adenomas (TSA), and mixed
polyps to serrated carcinoma (Noffsinger, 2009), that all have
a sawtooth-like (serrated) infolding of the neoplastic epithelium
in common (Makinen, 2007). Further typical characteristics of
serrated carcinomas are mucin secretion, absence of ‘‘dirty
necrosis,’’ lymphocytic infiltration and poor differentiation
(Huang et al., 2004; Jass et al., 2002). Because a very large
number of activating mutations of either KRAS or BRAF have
been detected as the earliest genetic alterations in serrated
lesions, activation of the RAS-RAF-MEK-ERK-MAP axis has
been suggested to be the initiating event in serrated carcinogen-
esis. In contrast to classical colonic tumors that show CIN,route to colorectal cancer is presumably caused byKRAS or
olonic tumors that morphologically and molecularly mimics
rovide what we believe to be an important tool for diagnostic
o far unanticipated relevance of oncogene-induced senes-
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Figure 1. Widespread Serrated Hyperplasia
but Lack of Hyperproliferation in K-rasG12D
Expressing Colon
(A) Average length of colons along the longitudinal
axis in LSL-K-rasG12D/+ (white bar) and K-rasG12Dint
(black bar) mice. Data are mean ± SE; n R 5;
***p < 0.001 by t test.
(B and C) Whole mount methylene blue stained
colon of (B) LSL-K-rasG12D/+ and (C) K-rasG12Dint
mice. Note that due to the lack of remaining normal
crypts, hyperplastic ones are not recognizable as
aberrant crypt foci or single polyps.
(D–G) H&E stained sections of (D and F) LSL-
K-rasG12D/+ and (E and G) K-rasG12Dint mice
demonstrating (E) pronounced proximal folds
and (mSH, G) crypt hyperplasia in colon of
K-rasG12Dint mice. Scale bars represent 100 mm
(D and E) and 50 mm (F and G).
(H) Epithelial cell number per 100 mm colonic mus-
cularis mucosae and (I) mitotic index in colon of
LSL-K-rasG12D/+ (white bars) and K-rasG12Dint
(black bars) mice.
All animals were analyzed at the age of 16 weeks.
Data are mean ± SE; n R 5; **p < 0.01 and not
significant (n.s.) by t test. See also Figure S1.
Cancer Cell
Oncogenic K-Ras in Serrated Colon Tumorigenesisserrated cancers are frequently characterized by a CpG island
methylator phenotype (CIMP) and subsequent high-level DNA
microsatellite instability (MSI-H) especially when located
proximally and associated with BRAF mutations (Cunningham
and Riddell, 2006). However, KRAS mutated tumors are more
frequently CIMP negative and MSI-L/MSS. A further mechanism
proposed to play a key role in the pathogenesis of these tumors
seems to comprise loss of the DNA mismatch repair gene
hMLH1 or the DNA repair gene O6-methylguanine DNA methyl-
transferase (MGMT) (Jass et al., 2002). Furthermore, it has
been speculated that senescence might occur in early tumor
stages preventing tumor progression (Jass, 2007), however,
functional evidence for this hypothesis is lacking. To test whether
we could recapitulate development of serrated tumorigenesis in
mice and to analyze the molecular events required for progres-
sion to cancer, we examined animals expressing oncogenic
K-rasG12D specifically in enterocytes.
RESULTS
Enterocyte-Specific Expression of K-rasG12D
Leads to Formation of Colonic Serrated Lesions
To establish whether intestinal epithelial cell (IEC)-specific
expression of oncogenic K-rasG12D would allow serrated tumor
formation, we crossed villin-Cre mice (Madison et al., 2002) to
LSL-K-rasG12D/+ mice (Jackson et al., 2001). The resulting mice,
termed K-rasG12Dint, were born at the expected Mendelian ratio
and did not display any overt developmental defects or weight
differences (data not shown). Macroscopic analysis of K-rasG12D
expressing intestines at 16 weeks of age displayed a significant
elongation of their large intestine (Figure 1A). In contrast to
LSL-K-rasG12D/+ control animals, whole mount analysis of meth-
ylene-blue stainedcolon fromK-rasG12Dintmice revealed irregular
crypt morphology (Figures 1B and 1C). Histological analysis of
K-rasG12Dint mice demonstrated occurrence of pronounced
proximal colonic folds (Figures 1D and 1E). More importantly, in136 Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc.K-rasG12Dint colons we detected the expected serrated, hyper-
plastic transformation (Figures 1Fand1G),whichwasnot patchy,
but rather uniformly spread along the whole large intestine
affecting nearly every single crypt. These hyperplastic crypts
closely resembled the histology found in human premalignant
lesions of the serrated route (see Figure S1 available online)
and we therefore refer to this histology as ‘‘murine serrated
hyperplasia’’ (mSH). Development of mSH occurred with a
100% penetrance and independently of gender or genetic back-
ground (C57BL/6;129 or after backcrossing to FVB/N for four
generations). Despite the marked hyperplasia in K-rasG12Dint
mice (defined by a significantly increased cell number/100 mm
muscularis mucosae, Figure 1H), we could not observe a differ-
ence in the colonic mitotic index determined by BrdU-labeling
compared to littermate control mice (Figure 1I), or in apoptotic
indexexaminedbystaining for active caspase3 (data not shown).
In small intestine (SI) of K-rasG12Dint mice length was signifi-
cantly increased along the longitudinal as well as the vertical
axis (Figure S2). In contrast to the colon of these mice, however,
villus elongation was associated with a higher proliferation and
migration rate determined by BrdU incorporation (Figure S2).
Further histological analysis of mutant SI revealed a high inci-
dence of villus branching and consistent with elongation along
the longitudinal axis, we frequently observed crypt fission
(Figure S2).
To test whether endogenous expression of K-rasG12D was
sufficient to promote colonic tumor growth along the serrated
route we monitored K-rasG12Dint up to 17 months. However, in
none of the K-rasG12Dint expressing colons, progression of the
mSH into more advanced tumor stages or carcinomas was
observed. In contrast, but consistent with a hyperproliferative
phenotype in the small intestine, 25% of K-rasG12Dint animals
(7/28) developed a single adenoma in the duodenum/jejunum
after 1 year (Figure S2 and Table S1).
Collectively, the endogenous expression of oncogenic K-ras
led to significant albeit distinct alterations in the architecture of
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Figure 2. Colonic mSH Are Characterized by Upregulation of
p16ink4a and OIS
(A–F) Biochemical analysis of isolated colonic enterocytes at 16 weeks. Acti-
vation assay of (A) Ras and (D) Ral. Immunoblot analysis of (B) Erk, (C) Akt,
and (E) p38 activation as well as immune complex kinase assay of (F) Jnk.
(G and H) Demonstration of OIS in mSH by SA-b-galactosidase assay on
frozen colonic sections of (G) LSL-K-rasG12D/+ and (H) K-rasG12Dintmice. Scale
bars represent 50 mm.
(I) Relative levels of p16ink4a, p19Arf, Dec1, and p53 mRNA levels in LSL-
K-rasG12D/+ (white bars) and K-rasG12Dint (black bars) mice. mRNA levels repre-
sent the mean ± SE of a minimum of three animals of each genotype.
(J) Immunoblot analysis of p16ink4a, p19Arf, p15ink4b, and b-actin. See also
Figure S2.
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Oncogenic K-Ras in Serrated Colon Tumorigenesisboth small and large intestine. Whereas in small intestinal IEC
K-rasG12D induced a persistent hyperproliferation and occasion-
ally development of adenomas, mutant colon was characterized
by the initiation of a presumably growth-arrested, serrated hyper-
plasia, which, however, did not progress into malignant tumors.
Oncogene-Induced Senescence Is Responsible
for Growth Arrest of Colonic mSH
Oncogene-induced senescence (OIS) is a form of stable growth
arrest that can be induced by overexpression of oncogenes in
cultured cells (Collado and Serrano, 2010). OIS can occur
in vivo in various premalignant lesions of malignant melanoma,
lymphoma, prostate, and lung cancer presumably having a tumor
suppressive function (Braig et al., 2005; Chen et al., 2005; Collado
et al., 2005; Michaloglou et al., 2005). Oncogenic K-ras mediated
Erk activation is one of the main inducers of senescence (Mooi
and Peeper, 2006), which might be the underlying cause for the
block of progression in mSH. To test this, we isolated IEC for
biochemical analysis. First, activation of K-ras in mutant IEC
was confirmed by pull-down assay of GTP-bound Ras
(Figure 2A). This led to the expected phosphorylation of Erk1/2
without affecting total protein levels of Erk (Figure 2B). In contrast,
activation of other downstream effectors of Ras, such as Akt and
Ral (Malumbres and Barbacid, 2003) remained either unchanged
or undetectable in colonocytes of mice of either genotype,
respectively (Figures 2C and 2D). Furthermore, we did not
observe any activation of the other MAP-kinases p38 or JNK
(Figures 2E and 2F), which had been found to be upregulated in
K-rasG12D expressing lungs (Lee et al., 2002), indicating that
endogenous expression of K-rasG12D in IEC primarily activates
Erk1/2. To test, whether K-ras mediated Erk-activation might
lead to senescence, we examined enzymatic activity of senes-
cence-associated (SA) b-galactosidase, a marker indicating
senescence both in vitro and in vivo (Dimri et al., 1995), in colons
of K-rasG12Dint mice and littermates. As hypothesized, mSH ex-
hibited strikingly elevated SA-b-galactosidase activity, which
was not observed in untransformed colons of control littermates
(Figures 2G and 2H). The presence of OIS was further supported
by upregulation of mRNA encoding the senescencemarker Dec1
(Figure2I) aswell as increasedp16ink4amRNAandprotein levels in
isolated colonic IEC of K-rasG12Dint mice (Figures 2I and 2J).
However, we could not detect upregulation of p19Arf or p53
mRNA (Figure 2I) or protein levels (Figure 2J and data not shown).
Incontrast, analysisof small intestinal IECdisplayedalso selective
phosphorylationof Erk, but in linewith theobservedhyperprolifer-
ation in K-rasG12D expressing SI, neither upregulation of p16ink4a
mRNA nor induction of senescence were observed (Figure S2).
Unlike our mousemodel that exhibits oncogenic K-ras starting
from embryonic day 12.5 dpc (Madison et al., 2002), tumor-initi-
ating mutations in human colon occur during adulthood.
To confirm that activation of oncogenic Kras in murine adult
IEC could still induce serrated hyperplasia, we crossed
LSL-K-rasG12D to inducible villin-creERT2/LSL-K-rasG12D/+ mice
(el Marjou et al., 2004). Similarly to K-rasG12Dint mice, activation
of Cre-recombinase in adult villin-creERT2/LSL-K-rasG12D/+
mice led to mSH development, upregulation of p16ink4a and
occurrence of OIS within 21 days after tamoxifen application
(Figure S3 and data not shown). Although an increased BrdU
incorporation was readily detectable within 6 days on firsttamoxifen administration in villin-creERT2/LSL-K-rasG12D/+ colon,
it was absent after 21 days (Figure S3) resembling the situation in
K-rasG12Dint mice.Loss of Ink4a/Arf Leads to Metastasizing Serrated
Cancer in K-rasG12Dint Mice
To functionally confirm the importance of OIS for the growth
arrest of mSH, we crossed K-rasG12Dint mice to Ink4a/ArfCancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc. 137
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Figure 3. Loss of Ink4a/Arf Allows Hyperproliferation and Tumor Progression in K-rasG12Dint Mice
(A) Mitotic index in Ink4a/Arf/ (white bar) and K-rasG12Dint/Ink4a/Arf/ (black bar) mice at 12 weeks; Data are mean ± SE; nR 4; ***p < 0.001 by t test.
(B and C) H&E stained sections of mice displaying (B) further deepening of proximal folds and (C) formation of traditional serrated adenoma. Scale bars represent
100 mm (B) and 50 mm (C).
(D) SA-b-galactosidase assay demonstrating loss of OIS. Scale bar represents 50 mm.
(E–K) Immunohistochemical and immunofluorescent staining of (E) BrdU, (F) MUC5AC, (G) CD3, (H) CD45, (I) cyclin D1, (J) b-catenin, and (K) c-myc. Scale bars
represent 50 mm (F–H) and 20 mm (I–K). See also Figure S3 and Table S1.
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Oncogenic K-Ras in Serrated Colon Tumorigenesisdeficient mice (Serrano et al., 1996) to generate K-rasG12Dint/
Ink4a/Arf/ (resulting in IEC-specific activation of K-rasG12D
and whole body deletion of Ink4a/Arf). Consistent with the upre-
gulation of p16ink4a in colonic but not small intestinal K-rasG12Dint
IEC, deletion of Ink4a/Arf induced colonic hyperproliferation
(Figure 3A), but left small intestinal morphology of K-rasG12Dint
mice unaffected. Furthermore, elongation of colonic proximal
folds was more pronounced on Ink4a/Arf-loss than in
K-rasG12Dintmice (Figure 3B, compare to Figure 1E). More impor-
tantly, within 12 weeks, in more than 50% of K-rasG12Dint/Ink4a/
Arf/mice (17/32), hyperplasia had progressed into tumors that
resembled traditional serrated adenomas (Figure 3C and
Figure S3) that were located exclusively in the proximal colon
(Table S1).
Loss of Ink4a/Arf-mediated senescence in murine serrated
adenomas was confirmed by the lack of SA-b-gal activity
(Figure 3D). Proliferating cells, determined by BrdU incorpora-
tion, were predominantly located in the lower half of crypts
(Figure 3E). Further immunohistochemical analysis of these
adenomas in K-rasG12Dint/Ink4a/Arf/ mice revealed aberrant
expression of MUC5AC (Figure 3F), suggesting differentiation
of mucous cells toward gastric surface mucous cells. Moreover,
we detected significant lymphocytic infiltration along the lamina
propria and surrounding the adenomatous epithelia determined
by immunofluorescent staining against CD3 and CD45 (Figures
3G and 3H). While epithelial cells stained positive for cyclin D1
(Figure 3I), b-catenin showed a membrane bound expression
pattern (Figure 3J) and these cells retained APC expression
(data not shown). Only few cells expressed nuclear c-myc (Fig-
ure 3K), collectively indicating that these tumors did not show
activation of the Wnt pathway. Remarkably, within 12 weeks
in 76%of theK-rasG12Dint/Ink4a/Arf/mice (13/17) with serrated138 Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc.adenomas, tumors had developed into fully invasive adenocarci-
nomas (Figures 4A–4C and Figure S4). These cancers were
exclusively located in the proximal colon and displayed a
highly proliferative and poorly differentiated phenotype (Fig-
ure 4D). Expression of cytokeratin (CK) 8/18 confirmed the
epithelial origin of these invasive cells (Figure 4E). Surprisingly,
expression of p53 was consistently positive in all colonic
serrated cancers (Figure 4F), however, we were not able to
detect any mutations when we sequenced exons 5–8 of Tp53
in laser-microdissected tumor DNA. In agreement with a
membranous expression of b-catenin, we also did not detect
any mutations in exon 3 of b-catenin that could lead to stabiliza-
tion of b-catenin. More importantly, 62% of these invasive
cancers (8/13) had metastasized to the lung (Figure 4G and
Table S1). Intestinal origin of these metastases was confirmed
by staining for CK 20 (Figure 4H).
Notably, by 12 weeks the majority of K-rasG12Dint/Ink4a/Arf/
mice became moribund showing signs of severe respiratory
distress. We therefore analyzed lungs of these animals and de-
tected also lung tumors in mice that did not have invasive
serrated cancer suggesting the existence of primary lung
adenomas. This was confirmed by positive immunohistochem-
ical staining for TTF-1, a marker, which is specifically expressed
in primary lung tumors, but not in colonic metastases and nega-
tive staining for CK7 (Figure S4). Recombination of the mutated
K-ras allele in primary lung adenomas was confirmed by PCR
analysis of DNA isolated from laser-capture microdissected
tumor tissue (data not shown). The early occurrence of primary
lung tumors limited a longer monitoring of K-rasG12Dint/Ink4a/
Arf/ mice.
To functionally examine the role of p53 in serrated tumor
development, we crossed K-rasG12Dint animals to conditional
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Figure 4. Rapid Development of CIMP Negative and MSS-L/MSS Serrated Adenocarcinomas that Metastasize to the Lung
in Ink4a/Arf-Deficient K-rasG12Dint Mice
(A–C) H&E stained sections of invasive carcinoma inK-rasG12Dint/Ink4a/Arf/micewith serration at the luminal surface (B) and invasion of epithelia (arrowhead, C)
through the lamina propria into the submucosa. Scale bars represent 200 mm (A) and 50 mm (B and C).
(D–F) Immunohistochemical staining of (D) BrdU, (E) CK8/18, and (F) p53. Scale bars represent 50 mm.
(G) H&E stained section of a lung metastasis of the primary tumor shown in (A). Scale bar represents 50 mm.
(H) Immunohistochemical staining of CK20 confirming intestinal origin of metastasis. Scale bar represents 50 mm.
(I) Venn diagram displaying the average number of methylated genes in colonic DNA isolated from control animals or serrated K-rasG12Dint/Ink4a/Arf/ cancers
(nR 3 of each genotype).
(J) Summary of the microsatellite stability (MSI) analysis comparing K-rasG12Dint/Ink4a/Arf/ cancers to healthy tissues from the same animals using five different
microsatellite repeat markers; white box indicates microsatellite stability (MSS), black box indicates MSI. See also Figure S4.
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Oncogenic K-Ras in Serrated Colon TumorigenesisTrp53 mice (Jonkers et al., 2001) to generate K-rasG12Dint/
Trp53Dint mice (resulting in specific activation of K-rasG12D and
concomitant deletion of Trp53 restricted to enterocytes).
Although about one-third of K-rasG12Dint/Trp53Dint mice (4/11)
developed small intestinal tumors within 1 year, we could not
observe tumor progression beyond the stage of hyperplasia in
the colon of these double mutants even when we monitored
them up to 12 months (Table S1). This was in agreement with
a missing upregulation of p19Arf or p53 in colonic mSH in
K-rasG12Dintmice (Figures 2I and 2J). Importantly, also additional
IEC-restricted deletion of Trp53 in K-rasG12Dint/Ink4a/Arf/mice
did not accelerate cancer development, despite the nuclear
accumulation of p53 in K-rasG12Dint/Ink4a/Arf/ cancers (data
not shown). Collectively, these data supported the notion that
the p16ink4a/Rb pathway but not the p19Arf/p53 pathway antag-
onizes colonic serrated tumor development.
Murine Serrated Cancers Are CIMP Negative
and MSI-L/MSS
Human serrated tumors harboring KRAS mutations frequently
exhibit a CIMP-low/CIMP-negative and microsatellite stable or
low profile (MSS/MSI-L) in contrast to tumors with BRAF muta-
tions that are characterized by extensive methylation of certainCpG islands (CIMP-high) and microsatellite instability (MSI-H)
(Jass, 2007). To determine methylation and microsatellite status
ofK-rasG12Dint/Ink4a/Arf/ serrated cancers, we enrichedmeth-
ylated DNA by MeDIP (methylated DNA immunoprecipitation)
from K-rasG12Dint/Ink4a/Arf/ tumor samples and control
animals before hybridization on a NimbleGen 385KMM8RefSeq
promoter array. Whereas a large number of genes were
commonly methylated in both groups, the overall number of
methylated genes was higher in DNA from control mice
(Figure 4I). None of the classic CIMP markers (Mint1, Mint2,
Mint31,Mlh1) or the more recently established markers defining
CIMP (Igf2, Cacna1g, Neurog1, Runx3, Socs1) (Weisenberger
et al., 2006) was methylated in control or tumor DNA indicating
that K-rasG12Dint/Ink4a/Arf/ cancers were CIMP negative. In
addition, mRNA levels encoding these various markers were
not significantly different in tumors compared to controls (data
not shown), supporting the notion that K-rasG12Dint/Ink4a/Arf/
tumors were indeed CIMP-negative.
To assess whether murine serrated cancers displayed MSI,
we compared DNA frommicrodissected tumors to DNA isolated
from tumor-free livers of the same animals using a panel of five
microsatellite repeat markers faithfully detecting MSI (Kabbarah
et al., 2003). The majority of tumors was either MSI-L (4/10) orCancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc. 139
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Oncogenic K-Ras in Serrated Colon TumorigenesisMSS (5/10) and only 1 of 10 analyzed tumors (no. 18161) fulfilled
the criteria for MSI-H (Boland et al., 1998) (Figure 4J).
Collectively, these data demonstrated that the murine K-ras
mutated cancers were CIMP-negative and MSS-L/MSS, thus
closely resembling the molecular characteristics of human
KRAS mutated serrated polyps and carcinomas.
Activation of Wnt Signaling Is Not Required for Murine
K-rasG12D Initiated Serrated Tumor Growth
Serrated adenocarcinomas are considered to develop indepen-
dently of Wnt activation in the majority of cases. Accordingly,
serrated tumors in K-rasG12Dint/Ink4a/Arf/ mice did not show
any activating Ctnnb mutations, loss of APC expression or
pronounced nuclear expression of b-catenin. To functionally
confirm that serrated tumor growth occurred independently of
Wnt activation, we injectedK-rasG12Dintmice six times intraperito-
neally (i.p.) once aweekwith azoxymethane (AOM). AOM is a pro-
carcinogen, which on metabolic activation leads to the formation
of O6-methyl-guanine-adducts and is commonly used in animal
models to induce classical colonic tumors (Boivin et al., 2003).
AOM is known to initiate mutations in exon 3 of Ctnnb, thereby
stabilizing b-catenin and subsequently activating Wnt signaling
(Greten et al., 2004). Because AOM primarily induces colonic
tumors we preferred this model to genetic models of sporadic
tumorigenesis, such as Apc mutants, which primarily develop
small intestinal tumors. Sixteenweeksafter the first AOM injection
animals were sacrificed and tumor incidence as well as tumor
morphology was determined. In contrast to the serrated cancers
that developed in K-rasG12Dint/Ink4a/Arf/ mice, all of the AOM-
induced adenomas were located in the distal colon, which is the
typical location of tumors following the classical pathway.
However, K-rasG12Dint mice developed 13-fold more tumors
compared to control littermates (Figure 5A) in agreement with
the notion that oncogenic K-ras enhances classical colon cancer
progression (Haigis et al., 2008; Janssen et al., 2006). The vast
majority of AOM-induced tumors were tubular andwell-differenti-
ated, displayed low to moderate dysplasia and none of themwas
invasive (Figures 5B and 5C). Sequence analysis of exon 3 of
Ctnnb in DNA isolated frommicrodissected tumor tissue revealed
activating mutations in tumors of either genotype (data not
shown). Accordingly, activation of Wnt signaling was further
confirmed by immunohistochemical stainings against b-catenin
and its downstream target c-myc, which both demonstrated
nuclear localization in tumors of either genotype (Figures 5D–
5G). To establish that AOM-induced tumorswere alsomolecularly
distinct from serrated cancers, we performed comparative gene
expression analysis on RNA samples isolated from serrated
cancers of K-rasG12Dint/Ink4a/Arf/ mice and classical, AOM-
induced tumors fromK-rasG12DintandLSL-K-rasG12D/+mice.Hier-
archical clustering of the samples revealed a significantly different
expressionprofile in serratedcancers compared toAOM-induced
tumors (Figure 5H). When we performed gene set enrichment
analysis (GSEA) to compare these gene expression profiles to
that of mice with an IEC-restricted deletion of Apc (Sansom
et al., 2007), theAOM-induced tumorsbut not the serrated tumors
demonstrated a high enrichment with the ‘‘Wnt signature’’ that is
reminiscent of classical tumors (Figure 5I) (Kaiser et al., 2007).
Recently, a gene expression profiling study demonstrated
that human serrated cancers comprise a distinct molecular140 Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc.subclass of colon cancers and several specific biomarkers
were identified (Laiho et al., 2007). When comparing serrated
cancers to conventional colon cancers it was suggested that up-
regulation ofHIF1a and its downstream target BNIP3L as well as
downregulation of EPHB2 and PTCH could be specifically found
in serrated cancers. Although it is not clear whether the serrated
cancers in this study contained KRAS or BRAF mutations, we
compared RNA expression levels of these biomarkers in murine
AOM-induced tumors and serrated cancers. Similarly to human
cancers, RNA levels coding for EphB2 were higher in classical
AOM-induced tumors whereas Hif-1a and Bnip3l mRNAs were
markedly upregulated in murine serrated cancers, yet expres-
sion of Ptch remained unchanged (Figure 5J and data not
shown). Immunohistochemical analysis confirmed the reciprocal
expression pattern of EphB2 and Hif-1a in tumor epithelium of
classical and serrated tumors (Figures 5K–5N).
Human KRAS Mutated Serrated Adenomas Show OIS
and Express High Levels of p16INK4A
Having established the importance of OIS and Ink4a/Arf in
murine serrated tumor development, we wanted to examine
whether senescence and p16INK4A upregulation might be
observed in human KRAS associated serrated carcinogenesis
as well. Therefore, we obtained during routine colonoscopy
18 hyperplastic polyps (HP), of which four contained a KRAS
(codon 12)mutation and as hypothesized, three of them revealed
a marked positive expression of SA-b-gal indicating OIS in HP
(Figure 6A). Furthermore, this was accompanied by p16INK4A
expression, which was undetectable in unaffected, healthy
mucosa (Figures 6C and 6D). To examine whether p16INK4A
upregulation was a general phenomenon commonly found in
KRAS mutated benign serrated lesions and whether tumor
progression was associated with loss of p16INK4A, we extended
our analysis to a cohort of 93 serrated tumors comprising hyper-
plastic polyps, sessile serrated adenomas, traditional serrated
adenomas, early invasive serrated adenocarcinomas within
a serrated adenoma and also advanced serrated adenocarci-
nomas with metastasis. We screened this cohort for the pres-
ence of KRAS (codon 12, 13) or BRAF (V600E) mutations and
identified 13 serrated tumors that contained mutated KRAS
(Table 1). Independently of tumor stage and grade of intraepithe-
lial neoplasia (dysplasia) all 13 KRASmutated tumors were MSS,
expressed MLH1 and except two cases displayed membranous
b-catenin expression indicating normal Wnt signaling (Table 1).
In nearly all samples we could detect robust expression of
p16INK4A that increased with degree of intraepithelial neoplasia
(dysplasia), whereas p14ARF was not expressed (Figures 7A–
7D). However, in three of four tumors that showed signs of
invasion p16INK4A expression was selectively reduced at the
infiltrative front of invasion and correlated inversely with expres-
sion of the proliferation marker Ki67 (Figures 7E and 7F). In one
advanced adenocarcinoma with metastasis, p16INK4A expres-
sion was completely lost. Decreased expression or loss of
p16INK4A was in most cases associated with CDKN2A promoter
methylation. Because we had observed nuclear accumulation of
p53 in murine advanced serrated tumors, we wanted to examine
whether we could recapitulate this unexpected finding in human
samples as well. Intriguingly, in almost all invasive cancers we
found nuclear accumulation of p53. Although in various cancers
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Figure 5. Oncogenic K-ras and Wnt Activation Cooperate in Classical but Not in Alternative Colon Carcinogenesis
(A) Tumor incidence in LSL-K-rasG12D/+ (white bar, n = 6) and K-rasG12Dint (black bar, n = 5) mice 16 weeks after the first of six AOM injections. Data aremean ± SE;
***p < 0.001 by t test.
(B and C) H&E stained sections of adenomas in (B) LSL-K-rasG12D/+ and (C) K-rasG12Dint mice.
(D–G) Immunohistochemical staining of (D and E) b-catenin and (F and G) c-myc.
(H) Two to threewhole colonic tumor RNA samples from individual micewere analyzed by Affymetrix MOE430A 2.0 expression profiling. RMA-normalized expres-
sion values were subjected to statistical analysis (Limma F test p value < 0.005) and filtered for absolute and relative changes between average expression values
(max/min > 2, max-min > 80). The resulting 1309 probe sets were Z-score normalized and subjected to hierarchical clustering; red indicates high expression,
green indicates low expression.
(I) GSEA analysis comparing classical AOM-induced tumors and serrated cancers reveals high similarity of AOM-induced tumors withApc-deficient IEC. Normal-
ized enrichment score: 2.83; p < 0.001.
(J) Relative levels of Ephb2, Hif-1a, and Bnip3l in classical AOM-induced tumors (white bars) and serrated cancers (black bars). mRNA levels represent the
mean ± SE of a minimum of three animals of each genotype.
(K–N) Immunohistochemical staining of (K, L) EphB2 and (M, N) Hif-1a in AOM-induced tumors and serrated cancers. In classical tumors epithelial cells express
EphB2 (K), but in serrated cancers only stromal cells are positive for EphB2, whereas tumor epithelia (arrowheads) remain negative (L). In contrast, Hif-1a displays
strong nuclear staining in (N) serrated tumor epithelia but not in (M) classical AOM-induced tumors. All scale bars represent 50 mm.
Cancer Cell
Oncogenic K-Ras in Serrated Colon Tumorigenesisincreased nuclear p53 accumulation is frequently caused by
TP53 mutations (Greenblatt et al., 1994), we could not detect
any mutations in the most commonly affected exons 5–8 of
TP53, resembling the situation in murine serrated cancers.
DISCUSSION
The majority of nonhereditary colorectal cancers follow a well-
defined tumor progression model involving APC mutation as
an initiating event. Mutation of K-ras occurs at later stages and
is supposedly not sufficient to initiate classical colonic tumori-genesis per se. We provide what we believe to be genetic
evidence that enterocyte specific expression of oncogenic
K-ras in mice can induce widespread colonic lesions that
morphologically resemble benign human serrated polyps. Our
results therefore support the hypothesis that indeed activation
of the RAS-RAF-MEK-ERK cascade may be the initiating event
in human serrated colorectal tumors.
Oncogene induced senescence has been suggested to have
a tumor suppressive function in a variety of different tumors
(Collado and Serrano, 2010). Although neither in primary human
colonic tissue nor in experimental models of colorectal cancerCancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc. 141
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Figure 6. HumanKRASMutated Benign Serrated Polyps Display OIS
and Express p16INK4A
(A and B) Positive staining for SA-b-gal indicating existence of OIS in a (A)
KRAS mutated hyperplastic polyp, but not in (B) healthy mucosa. Scale bars
represent 100 mm.
(C andD) Expression of p16INK4A in (C) the same SA-b-gal positive hyperplastic
polyp, but not in (D) healthy mucosa. Scale bars represent 50 mm.
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Oncogenic K-Ras in Serrated Colon Tumorigenesissenescence has been confirmed yet, OIS may provide a poten-
tial molecular mechanism explaining the rare progression of
benign early, serrated lesions toward serrated adenocarcinoma.
Indeed, we provide evidence that OIS developed in both hyper-
plastic mutant mouse tissue as well as in human serrated
polyps and this was paralleled by upregulation of p16. Similarly
to tumor progression in mice that was dependent on loss of
Ink4a/Arf, p16INK4A expression was either completely absent
or lost at the infiltrating front of invasion in the majority of human
invasive carcinomas. Furthermore, in tumors that did notTable 1. Summary of Morphological and Molecular Properties of 13
Tumor Type
KRAS
Mutation
BRAF
Mutation MSS MLH1 MGMT
Nuc
b-Ca
HP +  + + + 
SSA +  + + + 
TSA +  + + + 
TSA +  + + + 
TSA +  + + + 
TSA +  + + + 
TSA +  + + + 
Early inv. carc. in TSA +  + + + 
Early inv. carc. in TSA +  + + + 
Early inv. carc. in TSA +  + + + 
Serr. carcinoma +  + +  +
Serr. carcinoma +  + + + +
Adv. serr. carcinoma +  + +  
Adv. serr. carcinoma, advanced serrated carcinoma with metastasis; HP, hy
methylation; serr. carcinoma, serrated carcinoma; SSA, sessile serrated ade
is shown as follows: +, low expression; ++, moderate expression; +++, s
carcinoma.
142 Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc.express or displayed a reduced p16INK4A expression, CDKN2A
promoter methylation was commonly confirmed. Although we
cannot rule out that loss of Ink4a/Arf in stromal cells might affect
tumor progression in mice, in light of the findings in human
tissues our data strongly support the concept that OIS and
p16 upregulation confer tumor suppressive effects during
serrated tumorigenesis and suggest that loss of Ink4a/Arf could
be one key mechanism required to overcome growth arrest in
mutated cells. Because only 50% of K-rasG12Dint/Ink4a/Arf/
mice developed adenomas and carcinomas, presumably
additional genetic events are required for serrated tumor
progression apart from Ink4a/Arf loss. Based on our results
obtained with the AOM-model, which shifted the tumor type
toward classical tumorigenesis, activation of Wnt signaling
does not seem to play a major role in serrated cancer develop-
ment. Accordingly APC or CTNNB mutations are found
infrequently in human serrated polyps. However, one potentially
important candidate could be Mgmt, which is often found
inactivated in KRAS initiated serrated tumorigenesis
(Jass, 2007). Although in K-rasG12Dint mice Mgmt expression
was retained at all stages, it will still be interesting to functionally
examine the role of Mgmt as well as to identify other so far
unknown genes involved in serrated tumor progression in
these mice.
The mouse model we describe very closely mimics human
pathology and demonstrates many features of human serrated
polyps, i.e., proximal location, aberrant expression of gastric
mucous markers, lymphocytic infiltration and bottom-up
morphogenesis (Jass et al., 2002). Because serrated polyps
comprise a morphologically and molecularly heterogenous
group of tumors, we restricted our comparative analysis to
human KRAS mutated serrated lesions. Intriguingly, in addition
to the phenotypic similarities also the molecular alterations
were strikingly similar between our mouse model and the human
tumors. However, considering the fact that BRAF mutationsHuman KRAS Mutated Serrated Tumors
lear
tenin p14ARF p16INK4A
CDKN2A Prom.
Methyl. Nuclear p53
TP53
Mutation
  +  
 + +  
 +++   
 +++   
 +++   
 ++ +  
 ++ +  
 +++/  + 
 +++/ +  
 +++/  + 
 +++  + 
 +/ + + 
  + + 
perplastic polyp; inv. carc., invasive carcinoma; prom. methyl., promoter
noma; TSA, traditional serrated adenoma. Degree of p16INK4A expression
trong expression; +++/, strong expression with loss in early invasive
p16INK4a Ki67
E
A B
C D
F
Figure 7. Expression of p16 Increases with Degree of Dysplasia in
Human Serrated Polyps but Is Reduced in Early Invasive Carcinoma
and Correlates Inversely with Ki67 Expression
(A and B) Moderate p16INK4A expression (A) and inverse expression pattern of
Ki67 (B) in KRAS mutated traditional serrated adenoma (arrowheads).
(C and D) Strong p16INK4A expression in areas of serrated high-grade intraepi-
thelial neoplasia (dysplasia) (C, arrowheads) inversely correlates with Ki67
expression (D, arrowheads) in serial sections in the area of an early invasive
carcinoma within a sessile serrated adenoma.
(E and F) Reduced p16INK4A expression (E, arrowheads) and corresponding
increased Ki67 expression (F, arrowheads) in the infiltrating neoplastic cells.
All scale bars represent 50 mm.
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Oncogenic K-Ras in Serrated Colon Tumorigenesisoccur more frequently than KRAS mutations in human serrated
tumorigenesis, we cannot exclude that our results might be rele-
vant for the subgroup of KRAS-mutated serrated tumors only.
Nevertheless, OIS and p16INK4A could have an important func-
tion for the early stages of the alternative pathway to colon
cancer in general since a marked p16INK4A expression was
also detectable in a substantial number of BRAFmutated human
serrated polyps (L.K. and T.K., unpublished data).
Our results demonstrate a highly pronounced cell type speci-
ficity of oncogenic K-ras and unravel a clear difference between
small and large intestinal function of K-ras. Small intestinal
epithelial cells did not show OIS, Dec1, or p16 upregulation,
but they were characterized by persistent hyperproliferation
and the occurrence of sporadic tumors after 1 year. Conse-
quently, no small intestinal tumors were observed on loss of
Ink4a/Arf. In contrast, K-rasG12D expressing colon was charac-
terized by development of OIS that presumably occurred after
an initial brief period of hyperproliferation (compare proliferation
rates in inducible villin-creERT2/LSL-K-rasG12D/+mice 6 days and
21 days after induction; Figure S3) and led to the formation of
mSH, which did not progress unless Ink4a/Arf was deleted.Although K-rasG12D selectively activates Erk in both SI and colon,
OIS was induced only in colon, demonstrating the requirement
for expression of so far unidentified coexisting factors other
than Erk, that regulate senescence in the large intestine, but
not in the small intestine. These data also raise the question
how valid certain animals models are concerning colorectal
tumor development, in case these models develop tumors only
in small intestine.
To date no other genetic model addressing the function
of oncogenic K-ras in the intestine has addressed the
development of serrated tumorigenesis. Recent reports
demonstrated the occurrence of colonic hyperplasia in mice
expressing the same K-rasG12D mutant, however, serrated
tumors or the existence of OIS were not described (Haigis
et al., 2008; Trobridge et al., 2009). Furthermore, other studies
analyzing the function of intestinal K-ras made use of a trans-
genic approach (Janssen et al., 2006; Janssen et al., 2002),
which—albeit moderate overexpression levels of oncogenic
K-ras—might lead to the activation of additional downstream
signaling cascades. Moreover, when K-ras was activated using
an endogenous K-rasV12 mutant, Cre-recombinase was ex-
pressed under the control of a promoter that is preferentially
expressed in small intestine (Ireland et al., 2004; Sansom et al.,
2006), which could account for the different phenotypes
regarding the colon. Nevertheless, concerning the K-ras medi-
ated hyperproliferative phenotype in small intestine and in
respect to concomitant activation of oncogenic K-ras along
with Wnt signaling in either small or large intestine, our data
are in agreement with other reports (Haigis et al., 2008; Janssen
et al., 2006; Sansom et al., 2006).
Interestingly, murine and human serrated tumors consistently
displayed nuclear p53 accumulation in the absence of somatic
TP53 mutations. Especially in case of K-rasG12Dint/Ink4a/Arf/
mice this finding was unexpected because p19Arf can function
as an upstream activator of p53. Although the functional rele-
vance of this upregulation remains speculative, p53 may not
be an important tumor suppressor in our model because IEC-
specific deletion of Tp53 in K-rasG12Dint mice did not induce
progression of serrated hyperplasia. Moreover, when Tp53
was inactivated in IEC of K-rasG12Dint/Ink4a/Arf/ mice, tumor
progression was not further enhanced when compared to
K-rasG12Dint/Ink4a/Arf/ mice alone. Although p19Arf can
mediate certain functions independently of p53, our data
strongly suggest that the p16ink4a/Rb and not the p19Arf/p53
pathway mediate senescence in K-rasG12Dint mice.
In summary, we provide evidence that oncogenic K-ras
activation represents a key event during early Wnt-independent
serrated tumorigenesis in mice and suggest that upregulation of
p16INK4A and induction of OIS is a common phenomenon in
human KRAS mutated serrated tumor development. Thus,
we propose that loss of p16INK4A function for example by
promoter methylation can be one possibility to overcome
senescence thereby allowing tumor progression along the alter-
native, serrated route. Although there is no doubt anymore that
benign serrated lesions can progress into malignant stages, it
remains an important task to unravel useful markers that
distinguish those polyps that are likely to progress to cancer.
Our mouse model may represent an excellent tool to identify
some of them.Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc. 143
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Mice and Induction of Colonic Tumors
To express K-rasG12D in enterocytes, we crossed LSL-K-rasG12D (Hingorani
et al., 2003) to villin-Cre mice (both on a C57BL/6;129 background)(Madison
et al., 2002). Ink4a/Arf null (FVB/N.129) (Serrano et al., 1996) were obtained
from the MMHC, National Cancer Institute. K-rasG12Dint mice were back-
crossed for four generations on a FVB background before they were inter-
crossed with Ink4a/Arf null mice. Activation of K-rasG12D in villin-creERT2/
LSL-K-rasG12D/+ mice was achieved by five daily oral administrations of
1 mg tamoxifen in an ethanol/sunflower oil mixture. Six- to eight-week-old
mice (LSL-K-rasG12D and K-rasG12Dint) were injected i.p. with 15 mg/kg AOM
(NCI) once a week for 6 weeks. Sixteen weeks after the first injection animals
were sacrificed, colons were removed and analyzed as described (Greten
et al., 2004). In all experiments littermate controls were used assuring compar-
ison of mice on the same genetic background. All procedures conformed to
the regulatory standards and were approved by the Regierung von
Oberbayern. All human samples were obtained with the approval of the ethics
committee of the Technical University of Munich from subjects that had given
their written informed consent.
Determination of Proliferation and Migration Rates
Micewere injected i.p. with 100mg/kg BrdU (Sigma) 1.5 hr before sacrifice and
paraffin sections were stained using a-BrdU antibody (Amersham Bioscience
RPN201). For determination of migration rates, BrdU-injectedmice were sacri-
ficed after 48 hr. For each analysis BrdU-positive cells were scored in 12 full
crypts from two to five animals of each genotype.
MSI and Methylation Analysis
For examination of murine tissues PCR-based amplification of five microsatel-
lite repeat markers (Kabbarah et al., 2003) was performed using DNA isolated
from tumor tissue as well as healthy livers of the corresponding animals. For
analysis of human tissue mononucleotide markers BAT25 and BAT26 were
used (Deschoolmeester et al., 2008). Fluorescent PCR products were
analyzed by capillary electrophoresis using an ABI 3100 Genetic Analyzer
(Applied Biosystems) and 3130 Data Collection v3.0 software. Methylated
DNA immunoprecipitation and hybridization on a NimbleGen 385K MM8 Re-
fSeq promoter array was performed by imaGenes (GmbH, Berlin).
Laser Capture Microdissection
Laser capture microdissection and sequencing analysis of exon 3 of Ctnnb
and exons 5–8 of Tp53 were performed as described previously (Greten
et al., 2004).
Senescence Assay
Tissue was fixed in 4% paraformaldehyde for 2 hr on ice, washed twice with
PBS, and kept in 15% sucrose solution for 4 hr followed by an overnight incu-
bation in 30% sucrose at 4C. Samples were embedded in OCT and shock-
frozen. SA-b-galactosidase staining was performed on 6-mm cryosections
using the Senescence b-galactosidase staining kit (Cell Signaling 9860)
according to the manufacturer’s instructions.
Protein Analysis
Isolation of enterocytes, immunoblot analysis, and immune complex kinase
assay were essentially performed as described (Bollrath et al., 2009).
Ras and Ral activation assays were performed using the Ras Activation Assay
Kit (Upstate 17-218) or Ral Activation Assay kit (Upstate 17-300) according
to the manufacturer’s instructions. The following antibodies were used in
immunoblot analysis: a-phospho-Erk (9101), a-phospho-p38 (9211), a-phos-
pho-Akt (9271), a-Erk1/2 (9102),a-Akt (9272),a-p15INK4b (4822, Cell Signaling),
a-Jnk (PharMingen 554286), a-p38 (SC-535), a-p16ink4a (SC-1661), a-p19ARF
(Abcam ab80-50), and a-b-actin (A4700, Sigma).
Immunohistochemistry
Paraffin sections (3.5 mm) were stained using standard immunohistochemical
procedures. The following antibodies were used for murine tissues: a-cyclin
D1 (Santa Cruz SC-718), a-c-myc (SC-788), a-b-catenin (UBI 6734), a-p53
(Novocastra CM5), a-cytokeratin8/18 (Progen GP11), a-cytokeratin 7 (Progen144 Cancer Cell 18, 135–146, August 17, 2010 ª2010 Elsevier Inc.16090), a-cytokeratin 20 (Progen GP-K20), a-thyroid transcription factor-1
(Dako M3575), a-EphB2 (R&D Systems, AF467), a-HIF1a (Novus, NB 100-
131) a-CD45 (PharMingen 553089), a-CD3 (BD PharMingen 555274), and
a-MUC5AC (Neomarker MS-145). Immunohistochemical analysis of human
tissues was performed on a Benchmark XT (Ventana Medical Systems, Inc.)
using the following antibodies: a-MLH1 (BD PharMingen 551091), a-MGMT
(medac MS-470-P), a-b-catenin (Ventana 760-4242), a-p14ARF (CytoMed
Systems Mob456), a-p16INK4A (Diagnostic Biosystems Mob213), and a-p53
(NeoMarkers MS-186-Po).
RNA Analysis
The RNeasy Mini Kit (QIAGEN) was used for RNA extraction of isolated enter-
ocytes. Synthesis of cDNA was performed using SuperScript II Reverse Tran-
scriptase (Invitrogen). Real-time PCR analysis using Power SYBR Green PCR
MasterMix (Applied Biosystems) was performed on a StepOne Plus Real-Time
PCR system (Applied Biosystems). Primer sequences are available on request.
Gene expression profiling of tumor tissue was performed using Affymetrix
Gene ST GeneChips as reported before (Eckmann et al., 2008). In gene set
enrichment analysis (GSEA) we matched 87 transcripts that were upregulated
in Apc-deficient IEC (Sansom et al., 2007) to all transcripts from the Affymetrix
Mouse Genome 430A 2.0 Array, respectively. GSEA software is provided by
Broad Institute of MIT and Harvard University (http://www.broad.mit.edu/
gsea). We acknowledge the use of GSEA software (Subramanian et al.,
2005) to validate correlation between molecular pathways signatures in any
phenotype of interest. For analysis of gene sets we changed default parame-
ters as follows: permutation number to 1000; collapse data set to gene
symbols if ‘‘false’’; gene sets <1 and >2000 were excluded.
Statistical Analysis
Data are expressed as mean ± SEM. Differences were analyzed by unpaired,
two-tailed Student’s t test using Prism4 (GraphPad Software); p value% 0.05
were considered significant.
ACCESSION NUMBERS
Gene expression raw data is deposited in the GEO database under accession
number GSE20647.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and one table and can be
found with this article online at doi:10.1016/j.ccr.2010.06.013.
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